Figure 6.
PDGF-EVs protect muscle tissue from acute injury in vivo and reduce inflammation. (a) The representative hematoxylin-eosin images of gastrocnemius muscles of an ischemic hindlimb of the vehicle, cEV, or PDGF-EV treated animals 7 days after surgery (Original Magnification: × 200). (b) The quantitative analysis of muscle damage areas in hematoxylin-eosin stained gastrocnemius muscles of control and EV-treated ischemic hindlimbs at day 7 after surgery. PDGF-EVs significantly reduce muscle damage compared to vehicle or cEVs (mean ± SEM; *p < 0.05 vs. vehicle). (c) The representative immunofluorescence images (confocal microscopy) of CD14 + cells infiltration (red fluorescence) in gastrocnemius muscles of ischemic hindlimbs. (d) The quantitative analysis of immune cell infiltration in ischemic muscle tissue of control and EV-treated animals (mean ± SEM; **p < 0.01 vs. Vehicle). (e) The representative immunofluorescence images (confocal microscopy) of FoxP3 + cells (red fluorescence) in gastrocnemius ischemic muscles of control and EV-treated animals.